Clinical Trial Update: Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating alisertib (MLN8237) in combination with bortezomib for relapsed or refractory multiple myeloma has completed, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• MLN8237 (alisertib) (alisertib)

Snippet

Sponsor: Mayo Clinic | Conditions: Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-05-25